|
|
|
|
Delaware
|
|
|
|
46-4987888
|
||
(State or other jurisdiction of incorporation)
|
|
|
|
(I.R.S. Employer Identification No.)
|
||
|
5405 Windward Parkway
|
|
||||
|
Suite 100 South
|
|
||||
|
Alpharetta,
|
Georgia
|
30004
|
|
||
|
(Address of principal executive offices)
|
(Zip code)
|
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol
|
Name of exchange on which registered
|
Common Stock - $0.01 Par Value
|
AVNS
|
New York Stock Exchange
|
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
|
Item 9.01
|
Financial Statements and Exhibits
|
(d)
|
Exhibits.
|
Exhibit No.
|
|
Description
|
|
||
|
||
101.SCH
|
|
XBRL Taxonomy Extension Schema Document
|
101.CAL
|
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
101.DEF
|
|
XBRL Taxonomy Extension Definition Linkbase Document
|
101.LAB
|
|
XBRL Taxonomy Extension Label Linkbase Document
|
101.PRE
|
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
|
|
|
AVANOS MEDICAL, INC.
|
|
|
|
|
|
|
Date:
|
December 30, 2019
|
|
By:
|
/s/ S. Ross Mansbach
|
|
|
|
|
S. Ross Mansbach
Vice President, Deputy General Counsel and Corporate Secretary
|
|
5405 Windward Parkway
Alpharetta, GA 30004
T 1-844-4AVANOS
www.avanos.com
|
4
|
stock options, with a grant date value of $400,000 The number of options to be granted will be equal to the grant date value ($400,000) divided by the Black-Scholes value of the options on that date The strike price for the options will be equal to the closing stock price for Avanos shares on the grant date. Stock options will vest over a three-year period (30% year 1, 30% year 2, and $40% year 3)
|
4
|
performance-based restricted share units, with a grant date value of $600,000. The target number of performance-based share units to be granted will be equal to the grant date value ($600,000) divided by the closing stock price for Avanos shares on the grant date. Performance-based restricted share units will vest at the end of the three-year performance period (1/1/2020 -12/31/2022). The number of performance-based restricted share units that will ultimately vest will depend on the extent to which the performance metrics for those units have been met, as determined by the Compensation Committee after the end of the three-year performance period
|
/s/ Rhonda Gibby
|
|
Rhonda Gibby
Chief Human Resources Officer
|
|
/s/ Michael C. Greiner
|
|
Michael C. Greiner
December 13, 2019
|
|
|
|
|
|
|
Investor Contact: Dave Crawford
|
|
|
Avanos Medical, Inc.
|
|
|
470-448-5177
|
|
|
Investor.Relations@Avanos.com
|
|
|
|
|
|
Media Contact: Elizabeth Volpe
|
|
|
Brunswick Group
|
|
|
212-333-3810
|
|
|
Avanos@BrunswickGroup.com
|